Clinical trial
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating…
NCT00080795 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00080795 |
|---|---|
| Title | Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium |
| Official title | Phase II Trial of Neoadjuvant, Multi-Agent Chemotherapy For Locally Advanced Urothelial Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, conventional surgery, neoadjuvant therapy |
| Enrollment | 65 |
| Start date | Jul 1, 2001 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Apr 8, 2004 |
| Last update posted | Oct 22, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: